In this engaging breakfast symposium leveraging interactive educational technology, we invite our audience to interact with 4 thought leaders as they explore the exciting new therapeutic advancements for the management of pulmonary arterial hypertension (PAH). Faculty will share their expertise in the application of new agents and combinations of agents that can help slow disease progression and meet treatment goals for patients confronted with a PAH diagnosis.

This symposium is not sponsored, endorsed, or accredited by the American College of Chest Physicians.

Victor F. Tapson, MD, FRCP

Professor of Medicine, Director, Clinical Research, Women's Guild Lung Institute, Director, Venous Thromboembolism and Pulmonary Hypertension Research, Associate Director, Division of Pulmonary and Critical Care, Cedars-Sinai Medical Center, Los Angeles, California, United States

Paul R. Forfia, MD

Professor of Medicine, Lewis Katz School of Medicine, Director, Pulmonary Hypertension/Right Heart Failure and PTE Program, Temple University Hospital, Philadelphia, Pennsylvania, United States

Ronald J. Oudiz, MD

Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Director, Liu Center for Pulmonary Hypertension, Los Angeles Biomedical Research Institute, Harbour-UCLA Medical Center, Torrance, California, United States

Thenappan Thenappan, MD

Assistant Professor of Medicine, Center for Pulmonary Hypertension and Right Heart Failure, Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, United States

Date

Wednesday, November 1, 2017

Agenda

5:30AM - 5:50AM

Registration and Breakfast

5:50AM - 7:00AM

Program

Welcome and Introduction

Victor F. Tapson, MD

Tailoring Initial Treatment in PAH: New Paradigms and Perspectives

Paul R. Forfia, MD

Treatment Transitions in PAH: What Do the Latest Data Suggest?

Thenappan Thenappan, MD

Evaluating the Latest Evidence in PAH: Implications for Clinical Practice

Victor F. Tapson, MD

Complex Cases in PAH: Considerations for the Practicing Clinician

Ronald J. Oudiz, MD

Questions/Concluding Remarks

Victor F. Tapson, MD

Target Audience

This activity is intended for cardiologists, pulmonologists, and critical care specialists.

Goal Statement

The goal of this program is to increase clinical competence in the application of new therapeutic strategies for patients with PAH.

Learning Objectives

Upon completion of this activity, participants will

• Have increased knowledge regarding the
  • Latest clinical data in the setting of PAH
• Have greater competence related to
  • Tailoring initial therapy for patients with PAH
  • Adjusting PAH therapy in patients who are not meeting their treatment goals
  • Treating complex cases of PAH to optimize outcomes

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credits Available:
Maximum Of 1.25 AMA PRA Category 1 Credit(s)™

Medscape, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Sheraton Centre Hotel

Grand East Ballroom (Lower Concourse)

123 Queen St W, Toronto, ON M5H 2M9, Canada

Supported by independent educational grant from: